To this end, we treated HCT116 cells (colon carcinoma, wild type p53, activating truncation of Wip1 [20]) or an HCT116-derived cell line with targeted disruption of the p53-encoding genes [32] with the same drugs, alone or in combination. The gene discussed is TP53; the disease is colon carcinoma.